Vischer advises Oculis on its public listing on Nasdaq

Oculis Holding, a global biopharmaceutical company, purposefully driven to save sight and improve eye care, listed its shares on Nasdaq after successfully closing the business combination between European Biotech Acquisition Corp. (“EBAC”). At closing, Oculis had a pro-forma enterprise value of approximately USD 220m and a cash balance exceeding USD 117m prior to payment of final transaction costs.

Oculis is supported by leading new and existing institutional investors in the upsized PIPE financing including LSP 7, funds managed by Tekla Capital Management, Earlybird, Novartis Venture Fund, Pivotal Life Sciences, and VI Partners, among others.

VISCHER has advised as Swiss counsel with a team led by Matthias Staehelin (partner, pictured left) and Vincent Reardon (managing associate, pictured right) with Balthasar Müller, Timothy Woodtli, Natacha Tang, Sophie Zimmermann (all corporate/m&a) as well as Nadia Tarolli and Adrian Briner (both tax).

Vischer advises Oculis on its public listing on Nasdaq


Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2023 © All rights Reserved. Design by Origami Creative Studio


Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram